抗癌药物临床开发中慢性肾脏病受试者的纳入及其他肾脏相关考量:2015年至2019年获批抗癌药物的全景分析
该研究对2015年至2019年获批的55种抗癌药物及其74项关键试验进行全景分析,评估慢性肾脏病受试者纳入和肾小球滤过率评估方法。结果显示95%的关键试验含肾脏相关入选标准,68%基于肾小球滤过率,但仅29%和6%的药物分别在慢性肾脏病4-5期和血液透析患者中开展药代动力学分析。49%的药物说明书无肾脏剂量信息。
要点
- 95%的关键试验含肾脏相关入选标准,68%基于肾小球滤过率,中位肾小球滤过率下限为45 ml/min或45 ml/min/1.73 m²。
- 仅29%的药物在慢性肾脏病4-5期、6%在血液透析患者中开展药代动力学分析。
- 49%的药物说明书无肾脏剂量信息,肾脏相关不良事件报告差异大。
核心结论
- 慢性肾脏病受试者仍被排除在抗癌药物开发之外,关键试验和肾脏药代动力学分析中的肾小球滤过率估算仍不精确且异质。
- 肾脏相关安全性和剂量信息稀少且呈现不一致。
研究设计与样本
- 全景分析,纳入2015年至2019年获批的55种抗癌药物及其74项关键试验。
- 评估关键试验和药代动力学分析中慢性肾脏病受试者的纳入情况、肾小球滤过率评估方法及肾脏相关不良事件和剂量信息。
主要发现
- 95%的关键试验含肾脏相关入选标准,68%含基于肾小球滤过率的入选标准。
- 入选所需肾小球滤过率中位下限为45 ml/min或45 ml/min/1.73 m²。
- 仅29%的药物在慢性肾脏病4-5期、6%在血液透析患者中开展药代动力学分析。
- 超过60%的关键试验和超过80%的药代动力学分析使用估算肌酐清除率。
- 49%的药物说明书无肾脏剂量信息,肾脏相关不良事件报告高度可变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The US Food and Drug Administration has prioritized efforts to expand availability of therapies, including anticancer agents, for patients with CKD. US Food and Drug Administration Guidance recommends inclusion of study participants with CKD in clinical trials, improving pharmacokinetic characterization in people with decreased GFR, and using contemporary GFR assessment methods during drug development. We performed a landscape analysis of anticancer agents approved from 2015 to 2019 to evaluate inclusion of study participants with CKD and GFR assessment methods used during drug development and subsequent translation to kidney-related safety and dosing data in product labeling. METHODS: Oncology drugs approved from 2015 to 2019 and associated pivotal trials were identified. We evaluated inclusion of study participants with CKD in pivotal trials and pharmacokinetic analyses, investigated GFR assessment methods used for pivotal trial eligibility and renal pharmacokinetic analyses, and identified kidney-related adverse drug event and dosing information. RESULTS: A total of 55 drugs and 74 pivotal trials were included. Of the pivotal trials, 95% contained kidney-related eligibility criteria, including 68% with GFR-based eligibility. The median lower limit of GFR required for inclusion was 45 ml/min or ml/min per 1.73 m 2 . Pharmacokinetic analyses were performed in CKD stages 4-5 and hemodialysis for only 29% and 6% of drugs, respectively. Estimated creatinine clearance was used in over 60% and 80% of pivotal trials and pharmacokinetic analyses, respectively. Reporting of kidney-related adverse drug events was highly variable. Product labeling for 49% of drugs contained no kidney dosing information. CONCLUSIONS: Study participants with CKD continue to be excluded from anticancer drug development, and GFR estimation in pivotal trials and renal pharmacokinetic analyses remains imprecise and heterogeneous. Furthermore, kidney-related safety and dosing information is scarcely and inconsistently presented.
引用
- Butrovich MA, Reaves AC, Heyward J, et al. Inclusion of Participants with CKD and Other Kidney-Related Considerations during Clinical Drug Development: Landscape Analysis of Anticancer Agents Approved from 2015 to 2019. Clin J Am Soc Nephrol. 2023. PMID: 36723359. doi:10.2215/CJN.0000000000000105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。